One night, Tomas realizes that something may be very flawed. He went for a walk near his village on the identical paths he had walked countless times along with his friends, their comfortable voices echoing within the darkness of the night.
There were no street lights, and the streets were lit only by moonlight. This had never been an issue before, but suddenly Tomás realized that he couldn't clearly make out the perimeters of the trail. He stopped, hesitated, and tried to search out a reference, but the perimeters of his vision blurred. Without realizing it, Tomas had just experienced the primary symptom of retinitis pigmentosa: vision loss in low light, also often known as “night blindness.”
One in every 4,000 people worldwide suffers from this disease. retinitis pigmentosaAlthough we account for other rare genetic diseases that affect vision, the prevalence will be as high as one in 2,000.
How we perceive light and color.
The retina is the neurosensory tissue that lines the back of the attention. It forms during embryonic development as an outgrowth of the central nervous system, which opens outward in a cup-like shape to distinguish into separate layers of neurons which might be perfectly aligned and interconnected.
The retina is made up of the layer of neurons furthest from the sunshine source. Photoreceptor cells, cones and rodswhich will be activated by the impact of a photon (particle of sunshine). These cells are accountable for receiving light stimulation, converting it first right into a chemical signal after which into an electrical signal.
In total, the human retina has about 120 million rods and about 7 million cones.
Rods are the photoreceptor cells accountable for vision in low light, as they're stimulated by low photon intensities. These photons activate rhodopsin, a light-sensitive molecule.
Rodents cannot perceive color, and might only see in black and white. However, cones contain opsin proteins that reply to high intensities of photons, allowing us to see color.
Sakura/Shutterstock
Unequal distribution
Rods are distributed throughout the retina, while cones are concentrated primarily within the macula, which is positioned within the fovea, the central region of the retina. This high density of cones provides what's often known as visual acuity: extreme sensitivity to contrast.
At night, in dim light, only the bars are energetic. This is why we lose color vision and might't read when it gets dark, though our peripheral vision continues to be good.
But if we turn on a flashlight or stand under a street lamp, the high concentration of photons stimulates the cones, and we start to perceive colours and details as if it were daylight.
The brain tells us what we see.
In retinitis pigmentosa, mutations in genes essential for rod function mean these cells turn into damaged, stop working and eventually kill themselves in a process often known as programmed cell death. As a result, the lack of rods begins and regularly progresses from the outer to the inner layers.
In Tomás's case the disease progressed without him realizing it, until it reached the purpose where the lack of rod cells began to affect his visual perception. His night vision was affected, and he began to experience what's often known as tunnel vision: he found it difficult to locate objects around him, but he could still read and recognize details since the cones within the macula were still working.
In the long run, progression of the disease also affects the cones, resulting in total blindness.
Symptoms appear in adolescence.
Patients with retinitis pigmentosa normally begin to experience symptoms in late adolescence or early maturity. However, when mutations affect photoreceptor structural genes or occur during development, the condition can appear in childhood, as with Labor congenital amaurosis. Another congenital condition, Achromatopsiais characterised by immortality to see in color. The world is literally perceived in shades of gray.
In one other A rare retinal disorderlike Stargard diseaseThe mutations affect genes related to the cone or macula, which die first. This allows patients to see in low light, but they can't make out the main points of a human face.
Finding a cure
Currently, there isn't a approved treatment that may completely stop the progression of retinitis.
to do Designing and implementing specific state-of-the-art treatmentsWe have to conduct basic research into the genetic, biochemical and cellular processes which might be affected because of this of changes in retinal genes.
This is where biotechnology comes into play, because it allows us to research disease models. It will be done. One of two ways: by creating avatar mice (whose condition is being studied), or through the use of human retinal organoids (which permit us to access the human retina in a petri dish).
Based on these innovations, we'll have the ability to develop precision treatments targeting diseases attributable to specific genes or mutations – e.g. Luxturna, for RPE65 gene mutations. We may also have the ability to develop treatments that promote the survival of photoreceptors without targeting a particular gene or mutation, also often known as “agnostic” treatments.
These two methods offer the potential for treatment – ​​and even perhaps a cure – for Tomás in addition to other patients with rare retinal diseases like him.
